Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase I/II clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; and Sitravatinib, an investigational spectrum-selective kinase inhibitor that is in Phase II clinical trial for the treatment of NSCL cancer, as well as a KRAS G12D inhibitor program, which is in preclinical development. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and a clinical collaboration agreement with Novartis Pharmaceuticals Corporation. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.
IPO Year:
Exchange: NASDAQ
Website: mirati.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/10/2023 | $51.00 → $48.00 | Neutral → Buy | Citigroup |
| 8/9/2023 | $45.00 | Neutral → Buy | B. Riley Securities |
| 8/9/2023 | $45.00 | Overweight | Piper Sandler |
| 7/27/2023 | Sector Underperform | Scotiabank | |
| 5/25/2023 | Perform → Outperform | Oppenheimer | |
| 12/14/2022 | Hold | Needham | |
| 12/9/2022 | $121.00 → $53.00 | Buy → Neutral | Citigroup |
| 12/8/2022 | $110.00 → $59.00 | Outperform → Market Perform | BMO Capital Markets |
| 12/8/2022 | $94.00 → $65.00 | Overweight → Neutral | JP Morgan |
| 12/8/2022 | $94.00 → $65.00 | Outperform → Market Perform | BMO Capital Markets |
15-12G - Mirati Therapeutics, Inc. (0001576263) (Filer)
EFFECT - Mirati Therapeutics, Inc. (0001576263) (Filer)
EFFECT - Mirati Therapeutics, Inc. (0001576263) (Filer)
EFFECT - Mirati Therapeutics, Inc. (0001576263) (Filer)
S-8 POS - Mirati Therapeutics, Inc. (0001576263) (Filer)
S-8 POS - Mirati Therapeutics, Inc. (0001576263) (Filer)
S-8 POS - Mirati Therapeutics, Inc. (0001576263) (Filer)
S-8 POS - Mirati Therapeutics, Inc. (0001576263) (Filer)
S-8 POS - Mirati Therapeutics, Inc. (0001576263) (Filer)
S-8 POS - Mirati Therapeutics, Inc. (0001576263) (Filer)
Citigroup upgraded Mirati Therapeutics from Neutral to Buy and set a new price target of $48.00 from $51.00 previously
B. Riley Securities upgraded Mirati Therapeutics from Neutral to Buy and set a new price target of $45.00
Piper Sandler resumed coverage of Mirati Therapeutics with a rating of Overweight and set a new price target of $45.00
Scotiabank initiated coverage of Mirati Therapeutics with a rating of Sector Underperform
Oppenheimer upgraded Mirati Therapeutics from Perform to Outperform
Needham initiated coverage of Mirati Therapeutics with a rating of Hold
Citigroup downgraded Mirati Therapeutics from Buy to Neutral and set a new price target of $53.00 from $121.00 previously
BMO Capital Markets downgraded Mirati Therapeutics from Outperform to Market Perform and set a new price target of $59.00 from $110.00 previously
JP Morgan downgraded Mirati Therapeutics from Overweight to Neutral and set a new price target of $65.00 from $94.00 previously
BMO Capital Markets downgraded Mirati Therapeutics from Outperform to Market Perform and set a new price target of $65.00 from $94.00 previously
Submission status for MIRATI THERAPEUTICS, INC's drug KRAZATI (ORIG-1) with active ingredient ADAGRASIB has changed to 'Approval' on 12/12/2022. Application Category: NDA, Application Number: 216340, Application Classification: Type 1 - New Molecular Entity
Submission status for MIRATI THERAPEUTICS, INC's drug KRAZATI (ADAGRASIB) (ORIG-1) with active ingredient ADAGRASIB has changed to 'Approval' on 12/12/2022. Application Category: NDA, Application Number: 216340, Application Classification: Type 1 - New Molecular Entity
Submission status for MIRATI THERAPEUTICS, INC's drug KRAZATI (ADAGRASIB) (ORIG-1) with active ingredient ADAGRASIB has changed to 'Approval' on 12/12/2022. Application Category: NDA, Application Number: 216340, Application Classification: Efficacy